Mogrify ^Companies

Mogrify is an organization that aims to transform the lives of patients with degenerative diseases through a novel class of in vivo reprogramming therapies. They have developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming and the maintenance of cell identity. Their platforms, MOGRIFY and epiMOGRIFY, can predict the transcription factors and growth factors required to produce any target human cell type from any source human cell type. Mogrify is applying these platforms to generate functional cell types required to transform the lives of patients in areas such as ophthalmology, otology, metabolic diseases, and more. They are uniquely positioned to address the regenerative medicine market and are commercializing their technology through therapy development, co-development partnerships, and other applications.